Stryker Co. (NYSE:SYK) Shares Sold by UMB Bank n.a.

UMB Bank n.a. cut its position in shares of Stryker Co. (NYSE:SYK - Free Report) by 7.7% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 18,441 shares of the medical technology company's stock after selling 1,543 shares during the quarter. UMB Bank n.a.'s holdings in Stryker were worth $6,640,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of the business. Edgestream Partners L.P. purchased a new stake in Stryker during the 2nd quarter valued at $369,000. AE Wealth Management LLC increased its position in shares of Stryker by 101.8% during the 2nd quarter. AE Wealth Management LLC now owns 3,414 shares of the medical technology company's stock valued at $1,162,000 after purchasing an additional 1,722 shares during the last quarter. Pacer Advisors Inc. grew its position in Stryker by 8.4% during the second quarter. Pacer Advisors Inc. now owns 27,438 shares of the medical technology company's stock valued at $9,336,000 after buying an additional 2,122 shares during the period. Sei Investments Co. grew its position in shares of Stryker by 4.0% during the 2nd quarter. Sei Investments Co. now owns 168,336 shares of the medical technology company's stock valued at $57,271,000 after acquiring an additional 6,443 shares during the period. Finally, Thrivent Financial for Lutherans raised its holdings in Stryker by 69.7% in the 2nd quarter. Thrivent Financial for Lutherans now owns 87,244 shares of the medical technology company's stock worth $29,685,000 after purchasing an additional 35,833 shares during the period. 77.09% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on SYK. BTIG Research lifted their price objective on Stryker from $383.00 to $394.00 and gave the company a "buy" rating in a research report on Wednesday, October 30th. Robert W. Baird increased their price objective on shares of Stryker from $378.00 to $405.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 30th. Truist Financial upped their target price on shares of Stryker from $380.00 to $409.00 and gave the stock a "hold" rating in a report on Wednesday, December 18th. StockNews.com upgraded Stryker from a "hold" rating to a "buy" rating in a research report on Thursday, January 9th. Finally, UBS Group increased their target price on Stryker from $366.00 to $370.00 and gave the stock a "neutral" rating in a research report on Wednesday, October 30th. Four analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $405.80.

Insider Activity

In related news, CEO Kevin Lobo sold 57,313 shares of the company's stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the sale, the chief executive officer now owns 100,027 shares in the company, valued at $36,879,954.90. This represents a 36.43 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 5.90% of the company's stock.

Stryker Stock Up 0.6 %

Shares of SYK stock traded up $2.12 during mid-day trading on Monday, hitting $383.91. 1,727,106 shares of the stock traded hands, compared to its average volume of 1,070,245. The stock's fifty day moving average is $375.51 and its two-hundred day moving average is $359.17. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22. Stryker Co. has a 52-week low of $307.23 and a 52-week high of $398.20. The stock has a market cap of $146.35 billion, a P/E ratio of 41.15, a P/E/G ratio of 2.51 and a beta of 0.95.

Stryker (NYSE:SYK - Get Free Report) last announced its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.10. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The firm had revenue of $5.49 billion for the quarter, compared to the consensus estimate of $5.37 billion. During the same period in the previous year, the business earned $2.46 EPS. The firm's revenue for the quarter was up 11.9% on a year-over-year basis. Equities analysts predict that Stryker Co. will post 12.06 EPS for the current year.

Stryker Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be paid a dividend of $0.84 per share. This is an increase from Stryker's previous quarterly dividend of $0.80. This represents a $3.36 annualized dividend and a dividend yield of 0.88%. The ex-dividend date of this dividend is Tuesday, December 31st. Stryker's payout ratio is presently 36.01%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.